SCHEMBL5546209

SCHEMBL5546209

[CH2]c1nc2c(F)cccc2o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAGLA Q9Y4D2 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.35
PIK3CD O00329 1/20 0.34
PIK3CB P42338 1/20 0.34
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
GAA P10253 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 1/20 0.34
PRNP P04156 1/20 0.34
HPGD P15428 1/20 0.34
HSF1 Q00613 1/20 0.33
MAPT P10636 1/20 0.33
HRH4 Q9H3N8 2/20 0.31
AR P10275 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.30
PARP1 P09874 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6109454 0.79 DAGLA (0.41) DAGLASMN1; SMN2PIK3CDPIK3CBRAB9A
SCHEMBL3656157 0.76 DAGLA (0.40) DAGLASMN1; SMN2PIK3CDPIK3CBRAB9A
SCHEMBL5535607 0.76 CYP1A2 (0.36) SMN1; SMN2RAB9ANPC1KDM4EALDH1A1
SCHEMBL5537227 0.76 ELANE (0.41) KDM4EALDH1A1
SCHEMBL3656154 0.76 DAGLA (0.40) DAGLASMN1; SMN2PIK3CDPIK3CBRAB9A
SCHEMBL13279633 0.76 SMN1; SMN2 (0.43) DAGLASMN1; SMN2PIK3CDPIK3CBRAB9A
SCHEMBL5546211 0.76 ELANE (0.44) DAGLASMN1; SMN2PIK3CDPIK3CBRAB9A
SCHEMBL19808453 0.72 ELANE (0.44) DAGLASMN1; SMN2PIK3CDPIK3CBRAB9A
SCHEMBL9680689 0.72 PIK3CD (0.43) DAGLASMN1; SMN2PIK3CDPIK3CBRAB9A
SCHEMBL13058470 0.72 DAGLA (0.37) DAGLASMN1; SMN2PIK3CDPIK3CBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 DAGLA 4814/4885SMN1; SMN2 3985/4885PIK3CD 4528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.